Federal Judge Dismisses Patent Invalidity Declaratory Judgment Complaint

(July 11, 2016, 10:07 AM EDT) -- SAN FRANCISCO — Failed efforts by a nationwide provider of health care services for patients with AIDS to solicit generic drug manufacturers to develop products containing tenofir alafenamide fumarate (TAF) do not represent a sufficiently real and immediate dispute to confer standing in a declaratory judgment action with the TAF brand name manufacturer, a California federal judge concluded July 6 (AIDS Healthcare Foundation Inc. v. Gilead Sciences Inc., et al., No. 16-443, N.D. Calif.; 2016 U.S. Dist. LEXIS 87578).

(Decision available. Document #16-160718-007Z.)

In granting dismissal...
To view the full article, register now.